This recent drug does better than 3-6 months: Nivolumab . One-Third of Patients With Advanced Melanoma Survive at Least 5 Years After Nivolumab Treatment. (https://www.ascopost.com/issues/may-10-2016/one-third-of-pat...
Here's another recent success : https://hcp.lutathera.com/ --- https://www.nejm.org/doi/full/10.1056/NEJMoa1607427 At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the 177Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group.
Lutathera delivers a radioactive molecule to the tumor.